The Technical Analyst

Telomir Pharmaceuticals, [TELO]

Exchange: Nasdaq Sector: Healthcare Industry: Biotechnology

Telomir Pharmaceuticals, Price, Forecast, Insider, Ratings, Fundamentals & Signals

Current Signal: SELL (auto-tracking)

3.80% $6.28

America/New_York / 7 mai 2024 @ 16:00

FIND ALL MARKETS FIND ALL STOCKS LISTED @ Nasdaq Live Signal Oslo Live Signal Nasdaq Live Signal Crypto

Telomir Pharmaceuticals,: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap:	185.95 mill
EPS:	0
P/E:	0
Earnings Date:	N/A
SharesOutstanding:	29.61 mill
Avg Daily Volume:	0.0661 mill

PE RATIO: COMPANY / SECTOR
0.00x
Company: PE 0 \| sector: PE -3.05

PE RATIO: COMPANY / INDUSTRY
N/A
Company: PE 0 \| industry: PE 5.88

DISCOUNTED CASH FLOW VALUE
N/A
N/A

Expected Trading Range (DAY)
$ 5.09 - 7.47 ( +/- 18.95%)
ATR Model: 14 days

Forecast: 16:00 - $6.07

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $6.07

Forecast 2: 16:00 - $6.07

Forecast 3: 16:00 - $6.07

SCORE
10.00
Buy

Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022

Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD

Volume Signals
Price	$6.28 (3.80% )
Volume	0.0244 mill
Avg. Vol.	0.0661 mill
% of Avg. Vol	36.94 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Telomir Pharmaceuticals, Inc. Common Stock

Last 12 Months

RSI

Intraday RSI14 chart for Telomir Pharmaceuticals, Inc. Common Stock

Last 10 Buy & Sell Signals For TELO

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date	Signal	@	Closed	%
Feb 14 - 12:05	buy	$7.82	N/A	Active

TELO

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. It develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy recovery by interrupting and preventing the interleukin-17 induced inflammatory pathways. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. on October 10, 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.

Last 10 Buy Signals

Date	Signal	@
TWTUSD	May 7 - 18:17	$1.120
WHITEUSD	May 7 - 18:15	4 668.68
SFUNDUSD	May 7 - 18:17	$2.62
FXSUSD	May 7 - 18:17	$4.17
FNSAUSD	May 7 - 18:17	25.45
ORCAUSD	May 7 - 18:16	2.33
CGLDUSD	May 7 - 18:15	0.786
SETHUSD	May 7 - 18:04	3 025.89
RADUSD	May 7 - 18:12	$1.710
KCSUSD	May 7 - 18:11	$10.59

Latest Press Releases

2024-04-16 08:30:00 - Press Release

Telomir Pharmaceuticals Unveils Compelling Pre-clinical Data On Age-reversal Drug Telomir-1 At National Press Club Event In Washington, D.c.

Telomir-1 elongates telomere caps on human normal embryonic fibroblast cells by stimulating the enzyme telomerase that protects the dna and genetic material in chromosomes to combat aging

2024-04-02 08:30:00 - Press Release

Telomir Pharmaceuticals' Anti-aging Expert And Nyt Bestselling Author Michael F. Roizen, Md, To Present Promising Pre-clinical Data For Age-reversal Drug Telomir-1 At The National Press Club In Washington, Dc, On April 15, 2024

Telomir's pre-clinical studies demonstrate its lead development product, telomir-1, elongates telomere caps on human normal embryonic fibroblast cells by stimulating the enzyme telomerase

2024-03-29 16:44:00 - Press Release

Update – Telomir Pharmaceuticals Announces Collaboration With Argenta To Study Osteoarthritis In Canines

Study to determine the efficacy of telomir-1 on mitigating the clinical signs of osteoarthritis and other age-related diseases

2024-03-26 08:30:00 - Press Release

Telomir Pharmaceuticals Announces Collaboration With Argenta To Study Osteoarthritis In Canines

Study to determine the efficacy of telomir-1 on mitigating the clinical signs of osteoarthritis and other age-related diseases

2024-03-22 08:30:00 - Press Release

Telomir Pharmaceuticals Releases New Pre-clinical Data For Telomir-1 To Be Presented At The Global Longevity Federation Conference In Las Vegas On March 26th

Poster presentation delivers pre-clinical results that demonstrate that its lead development product, telomir-1, elongates telomere caps on human normal embryonic fibroblast cells

Latest News

2024-04-02 08:30:00 - GlobeNewsWire

Telomir Pharmaceuticals' Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024

Telomir's pre-clinical studies demonstrate its lead development product, Telomir-1, elongates telomere caps on human normal embryonic fibroblast cells by stimulating the enzyme telomerase

Full Story

2023-12-16 12:25:03 - Seeking Alpha

IPO Update: Telomir Pharmaceuticals Proposes IPO Terms

Telomir Pharmaceuticals plans to raise $7 million through an IPO to fund its development of treatments for age-related inflammatory conditions. The company's lead candidate, TELOMIR-1, has the potential to act as an Interleukin-17 inhibitor for conditions such as hemochromatosis and osteoarthritis. Given TELO's thin capitalization, high valuation expectations and early stage of development, my opinion on the IPO is to Sell [Avoid].

Full Story

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.